Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Renapharma AB
AB
Active
Org 5565718946
Riddargatan 16, 114 51
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 1999 · 27 years old
4 employees
Overvåg
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Renapharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
10M
21M
31M
41M
17M
2020
23M
2021
30M
2022
30M
2023
36M
2024
EBITDA
SEK millions
11M
8M
6M
3M
0M
3M
2020
9M
+200%
2021
8M
-11%
2022
7M
-12%
2023
8M
+14%
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
17 225
23 103
30 159
30 205
35 635
Staff expenses
—
—
−7 472
−3 606
−3 784
EBITDA
2 745
9 218
7 899
7 171
7 867
Depreciation & amort.
−886
−1 146
−534
−538
−2 801
EBIT
1 859
8 072
7 365
6 633
5 066
Net financials
−215
−128
9
−29
280
Profit before tax
1 644
7 962
7 374
6 603
4 589
Tax
−0
−0
—
—
−469
Net profit
1 644
7 962
7 374
6 603
4 120
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
21 408
25 991
37 136
44 263
41 324
Equity
4 559
12 520
19 894
26 497
30 617
Long-term debt
11 505
11 373
9 534
8 102
5 789
Short-term debt
5 344
2 098
7 708
9 664
4 160
Total debt
16 849
13 471
17 242
17 766
9 949
Financial ratios
5-year trend
EBITDA-margin
22.1%
This company
15.8%
Market median
+40% vs market
2020
2024
Soliditetsgrad
74.1%
This company
38.2%
Market median
+94% vs market
2020
2024
Egenkapitalforrentning
13.5%
This company
18.4%
Market median
+27% vs market
2020
2024
Nettoresultatgrad
11.6%
This company
8.1%
Market median
+43% vs market
2020
2024
Aktivomsætning
0.86×
This company
1.12×
Market median
+23% vs market
2020
2024
Gæld/egenkapital
0.35×
This company
0.62×
Market median
+44% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Renapharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
